{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Khairkhah N"],"funding":["National Institute of Neurological Disorders and Stroke","National Institutes of Health","Chadtough Foundation"],"pagination":["101278"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12918168"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["73"],"pubmed_abstract":["<h4>Introduction</h4>Diffuse midline glioma (DMG) with the H3K27M mutation remains one of the most treatment-resistant pediatric brain tumors, in part due to limited antigen presentation and immune visibility. Exploring how glioma biology and therapeutic interventions influence immune recognition offers new opportunities to identify tumor-specific immune targets.<h4>Materials and methods</h4>We performed immunopeptidomics on human cell line derived tumor tissue for DMG and glioblastoma (GBM) and defined how MTX-241F, a selective EGFR/PI3K inhibitor, changes the tumor immunopeptidome. Immunopeptides were isolated from xenografted tumors by capturing MHC-I bound peptides followed by mass spectrometry. Comparative analyses were performed across tumor type (DMG vs. GBM) and treatment condition"],"journal":["Neoplasia (New York, N.Y.)"],"pubmed_title":["Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG)."],"pmcid":["PMC12918168"],"funding_grant_id":["1R01NS13151501"],"pubmed_authors":["Nyayapathy S","Owolabi H","Rumble JM","Sebolt-Leopold JS","Ibrahim MMH","Namvar A","Everest-Dass A","Khairkhah N","Jones R","Galban S","Whitehead CE"],"additional_accession":[]},"is_claimable":false,"name":"Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG).","description":"<h4>Introduction</h4>Diffuse midline glioma (DMG) with the H3K27M mutation remains one of the most treatment-resistant pediatric brain tumors, in part due to limited antigen presentation and immune visibility. Exploring how glioma biology and therapeutic interventions influence immune recognition offers new opportunities to identify tumor-specific immune targets.<h4>Materials and methods</h4>We performed immunopeptidomics on human cell line derived tumor tissue for DMG and glioblastoma (GBM) and defined how MTX-241F, a selective EGFR/PI3K inhibitor, changes the tumor immunopeptidome. Immunopeptides were isolated from xenografted tumors by capturing MHC-I bound peptides followed by mass spectrometry. Comparative analyses were performed across tumor type (DMG vs. GBM) and treatment condition","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T09:22:05.587Z","creation":"2026-07-09T10:47:11.595Z"},"accession":"S-EPMC12918168","cross_references":{"pubmed":["41643293"],"doi":["10.1016/j.neo.2026.101278"]}}